EAPI

FR0014008VX5

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:28 2024-05-10 am EDT			5-day change	1st Jan Change
3.106 ^EUR	-0.19%		+7.40%	-45.79%

Apr. 10	Euroapi Names New Chief Commercial Officer	MT
Apr. 10	Euroapi: tightening of executive committee	CF

Euroapi S.A.(ENXTPA:EAPI) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)

May 11, 2022 at 12:00 am EDT

Latest news about EUROAPI

Euroapi Names New Chief Commercial Officer	Apr. 10	MT
Euroapi: tightening of executive committee	Apr. 10	CF
Euroapi S.A. Announces Executive and Executive Committee Changes	Apr. 09	CI
CAC40: ends in green, approaches 8200 points	Mar. 26	CF
CAC40: +0.3%, tops out at 8,180, same gap for US indices	Mar. 26	CF
CAC40: records in sight 48 hours before end of 1st quarter	Mar. 26	CF
Euroapi: Kopernik Global Investors crosses the 5% threshold	Mar. 19	CF
CAC40: falls back to equilibrium at the end of the session, +1.7% over the week	Mar. 15	CF
EUROAPI : Oddo lowers its target price	Mar. 15	CF
Euroapi: share price falls 16% after Brindisi shutdown	Mar. 15	CF
CAC40: 4 witches outperform, W-Street struggles	Mar. 15	CF
CAC40: clings to 8,200 for the '4 Witches' despite rates	Mar. 15	CF
CAC40: cautious trend before a salvo of statistics	Mar. 15	CF
CAC40: Slightly negative bias ahead of the 4 witches' day	Mar. 15	CF
Euroapi: production suspended in Brindisi	Mar. 15	CF
Euroapi Halts Pharmaceutical Ingredient Production at Italian Site Amid Quality Control Issues	Mar. 15	MT
Deutsche Bank Downgrades Euroapi to Sell from Hold, Cuts PT	Mar. 05	MT
EUROAPI : Deutsche Bank downgrades to 'sell	Mar. 05	CF
Euroapi: further decline, Deutsche Bank concerned	Mar. 05	CF
CAC40: closes at half-mast despite morning record	Feb. 29	CF
Nexity: crisis measures stepped up, share price falls	Feb. 29	CF
Euroapi: transformation program and new CEO	Feb. 29	CF
Euroapi: sharply widened net loss in 2023	Feb. 29	CF
Euroapi S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Euroapi: MAK Capital One exceeds 5% threshold	Feb. 15	CF

EUROAPI specializes in the development and manufacture of active pharmaceutical ingredients on behalf of healthcare industries. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. EUROAPI has 6 production sites located in France (2), the United Kingdom, Germany, Italy and Hungary.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Tides USA Conference

Related indices

CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Ratings for EUROAPI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.106 EUR

Average target price

3.52 EUR

Spread / Average Target

+13.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EUROAPI	-45.79%	317M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

EUROAPI

Equities

EAPI

FR0014008VX5

Pharmaceuticals

Euroapi S.A.(ENXTPA:EAPI) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)

Latest news about EUROAPI

Chart EUROAPI

Company Profile

Income Statement Evolution

Ratings for EUROAPI

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals